| Barry Philip Fisher, MD | |
|
140 Lincoln Ave, Haverhill, MA 01830-6700 | |
| (978) 374-2000 | |
| Not Available |
| Full Name | Barry Philip Fisher |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 48 Years |
| Location | 140 Lincoln Ave, Haverhill, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265452320 | NPI | - | NPPES |
| 714366 | Other | MA | TUFTS HEALTH PROGRAM |
| 2061317 | Medicaid | MA | |
| E29041 | Other | MA | BLUE CROSS & BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 42687 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Shore Health Express Inc | 6406108836 | 33 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson's Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.
COMS Interactive, also known as Clinical Outcomes Management Systems, has launched the Outcomes Performance Achievement Leader (OPAL) Award program. The program is an extension of the company's focus on improving health care and clinical outcomes in the long-term care marketplace by leveraging Daylight IQ™, the COMS' flagship Disease Management Product Suite.
The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease - mineral and bone disorder (CKD-MBD) in a growing collection.
The demise of St. Vincent's Hospital in Greenwich Village two years ago has led to a struggle for health care supremacy in some of New York's most distinctive neighborhoods, offering a glimpse, in the process, at what might be the future of urban medicine.
› Verified 2 days ago
| Entity Name | Steward Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780971275 PECOS PAC ID: 0244401404 Enrollment ID: O20110919000768 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson's Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.
COMS Interactive, also known as Clinical Outcomes Management Systems, has launched the Outcomes Performance Achievement Leader (OPAL) Award program. The program is an extension of the company's focus on improving health care and clinical outcomes in the long-term care marketplace by leveraging Daylight IQ™, the COMS' flagship Disease Management Product Suite.
The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease - mineral and bone disorder (CKD-MBD) in a growing collection.
The demise of St. Vincent's Hospital in Greenwich Village two years ago has led to a struggle for health care supremacy in some of New York's most distinctive neighborhoods, offering a glimpse, in the process, at what might be the future of urban medicine.
› Verified 2 days ago
| Entity Name | South Shore Health Express Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477044212 PECOS PAC ID: 6406108836 Enrollment ID: O20181115000152 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson's Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.
COMS Interactive, also known as Clinical Outcomes Management Systems, has launched the Outcomes Performance Achievement Leader (OPAL) Award program. The program is an extension of the company's focus on improving health care and clinical outcomes in the long-term care marketplace by leveraging Daylight IQ™, the COMS' flagship Disease Management Product Suite.
The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease - mineral and bone disorder (CKD-MBD) in a growing collection.
The demise of St. Vincent's Hospital in Greenwich Village two years ago has led to a struggle for health care supremacy in some of New York's most distinctive neighborhoods, offering a glimpse, in the process, at what might be the future of urban medicine.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Barry Philip Fisher, MD 1 Edward St, Canton, MA 02021-2303 Ph: (781) 828-3533 | Barry Philip Fisher, MD 140 Lincoln Ave, Haverhill, MA 01830-6700 Ph: (978) 374-2000 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson's Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.
COMS Interactive, also known as Clinical Outcomes Management Systems, has launched the Outcomes Performance Achievement Leader (OPAL) Award program. The program is an extension of the company's focus on improving health care and clinical outcomes in the long-term care marketplace by leveraging Daylight IQ™, the COMS' flagship Disease Management Product Suite.
The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease - mineral and bone disorder (CKD-MBD) in a growing collection.
The demise of St. Vincent's Hospital in Greenwich Village two years ago has led to a struggle for health care supremacy in some of New York's most distinctive neighborhoods, offering a glimpse, in the process, at what might be the future of urban medicine.
› Verified 2 days ago
Byron Earle Brumbaugh, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 140 Lincoln Ave, Haverhill, MA 01830 Phone: 978-374-2000 | |
Peter Alexander Bevins, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 140 Lincoln Ave, Haverhill, MA 01830 Phone: 978-374-2000 |